Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Jayempi vs Imurek in Healthy Adults
NCT03930264Phase 1Completed
- Sponsor
- Nova Laboratories
- Start
- Apr 2019
- Primary completion
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of cyclophosphamide or azathioprine in transplant rejection, rheumatoid arthritis (RA) and inflammatory bowel disease (IBD) (2 arms), sponsored by Nova Laboratories. Primary endpoints: Maximum Observed Plasma Concentration at 18 hours, Area under the plasma concentration-time curve from time zero to time t at 18 hours and 1 more. Started Apr 2019; status: completed.
02
Drugs
cyclophosphamide or azathioprine
03
Conditions
transplant rejectionrheumatoid arthritis (RA)inflammatory bowel disease (IBD)
Beyond the preview
Go deeper on NCT03930264.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03930264.